Candesartan Cilexetil
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
- Candesartan Cilexetil
- Pharmacist Assessment Report
- Candesartan Cilexetil: Angiotensin II type 1 receptor blocker → malignant hypertensive renal disease
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Candesartan Cilexetil: Angiotensin II type 1 receptor blocker → malignant hypertensive renal disease
One-Sentence Summary
Candesartan cilexetil is an angiotensin II type 1 receptor blocker (ARB) marketed in Canada. The TxGNN model predicts it may be effective for malignant hypertensive renal disease, but no clinical trials and no publications directly study this disease, so the support is model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | malignant hypertensive renal disease |
| TxGNN Prediction Score | 0.9968 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs on record: at least 18; dormant: 2) |
| Number of DINs | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on its drug class, candesartan blocks the angiotensin II type 1 receptor, which is part of the renin-angiotensin-aldosterone system (RAAS).
Malignant hypertensive renal disease involves accelerated hypertension with kidney injury, and RAAS overactivation is thought to contribute. Blocking this pathway is therefore mechanistically plausible.
This reasoning is class-level and indirect. No disease-specific clinical data were found, and the high score reflects a model prediction, not validated evidence. The prediction is best treated as a research question.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
The data compiled for this report list 20 valid single-ingredient licences (the list may be partial). No dosage form or indication text is recorded for them.
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02239092 | ATACAND | Not recorded | Not recorded |
| 02239090 | ATACAND | Not recorded | Not recorded |
| 02388715 | CANDESARTAN | Not recorded | Not recorded |
| 02366320 | TEVA-CANDESARTAN | Not recorded | Not recorded |
| 02326957 | SANDOZ CANDESARTAN | Not recorded | Not recorded |
Safety Considerations
Package insert warnings, contraindications and drug interaction data were not available. Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The main prediction rests only on a model score and class-level reasoning. No trial or publication studies malignant hypertensive renal disease directly, so the evidence level is L5.
To proceed, the following is needed:
- Disease-specific clinical or preclinical studies of candesartan in malignant hypertensive renal disease
- Mechanism of action data
- Package insert warnings and contraindications from Health Canada
- A review of renal safety (e.g., renal function, potassium) in patients with severe kidney impairment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.